(Updates the headline and first paragraph with latest company filing.)
Novavax (NVAX) said Wednesday it is still awaiting a decision from the US Food and Drug Administration on its biologics license application for its Covid vaccine.
The vaccine approval is in limbo after the FDA missed a deadline, but a decision could be any day, The Wall Street Journal reported earlier.
The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a full approval, the report said, citing sources.
FDA did not immediately respond to requests for comment from MT Newswires.
NVAX shares were up 3% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。